Does Dr. ROBERT ADRAH have financial conflicts of interest?

Dr. ROBERT ADRAH (MD) has received a total of $792 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $792 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ROBERT ADRAH?

According to CMS Open Payments data, Dr. ROBERT ADRAH received funding from BAYER HEALTHCARE PHARMACEUTICALS ($243), BOEHRINGER INGELHEIM PHARMACEUTICALS ($122), and CALLIDITAS THERAPEUTICS US ($115).

Does Dr. ROBERT ADRAH receive research grants or speaking fees?

Dr. ROBERT ADRAH has received $792 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. ROBERT ADRAH

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: ROCK HILL, SC 29732

NPI Number: 1629499785

LIFETIME INDUSTRY VALUE

$792

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ADRAH is a verified Internal Medicine, Nephrology practitioner based in ROCK HILL, SC.

Between 2021 and 2024, Dr. ADRAH had an overall industry promotional and research financial footprint of $792 as recorded in the federal CMS Open Payments database.

$792 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ADRAH's primary funding source is BAYER HEALTHCARE PHARMACEUTICALS, which accounts for $243 (representing 30.7% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

BAYER HEALTHCARE PHARMACEUTICALS

Rank 1

$243

30.7%

BOEHRINGER INGELHEIM PHARMACEUTICALS

Rank 2

$122

15.4%

CALLIDITAS THERAPEUTICS US

Rank 3

$115

14.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.